Format

Send to

Choose Destination
ACS Med Chem Lett. 2013 Dec 10;5(2):143-8. doi: 10.1021/ml400397k. eCollection 2014 Feb 13.

Design, synthesis, and osteogenic activity of daidzein analogs on human mesenchymal stem cells.

Author information

1
Center for Stem Cell Research and Regenerative Medicine, Tulane University School of Medicine , New Orleans, Louisiana 70112, United States.
2
Department of Chemistry and RCMI Cancer Research Program, Xavier University , New Orleans, Louisiana 70125, United States.
3
Southern Regional Research Center , U.S. Department of Agriculture, New Orleans, Louisiana 70130, United States.
4
Department of Medicine, Tulane University School of Medicine , New Orleans, Louisiana 70112, United States.

Abstract

Osteoporosis is caused by an overstimulation of osteoclast activity and the destruction of the bone extracellular matrix. Without the normal architecture, osteoblast cells are unable to rebuild phenotypically normal bone. Hormone replacement therapy with estrogen has been effective in increasing osteoblast activity but also has resulted in the increased incidence of breast and uterine cancer. In this study we designed and synthesized a series of daidzein analogs to investigate their osteogenic induction potentials. Human bone marrow derived mesenchymal stem cells (MSCs) from three different donors were treated with daidzein analogs and demonstrated enhanced osteogenesis when compared to daidzein treatment. The enhanced osteogenic potential of these daidzein analogs resulted in increased osterix (Sp7), alkaline phosphatase (ALP), osteopontin (OPN), and insulin-like growth factor 1 (IGF-1), which are osteogenic transcription factors that regulate the maturation of osteogenic progenitor cells into mature osteoblast cells.

KEYWORDS:

BMSCs; Daidzein analogs; mesenchymal stem cells; osteogenesis

Supplemental Content

Full text links

Icon for American Chemical Society Icon for PubMed Central
Loading ...
Support Center